https://nl.marketscreener.com/koers/aandeel/DAIICHI-SANKYO-CO-LTD-6498062/nieuws/AstraZeneca-en-Daiichi-Sankyo-s-Biologics-License-Application-voor-Datopotamab-Deruxtecan-geacceptee-45984432/?utm_source=telegram&utm_medium=social&utm_campaign=share